STATEMENT OF NEED/TARGET AUDIENCE

Approximately 40,000 new cases of renal cell cancer (RCC) occur annually, with 13,000 deaths due to the disease. Recently, increased understanding of the biology of RCC and emerging clinical trial results have led to the emergence of new therapeutic options for patients. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well informed of these advances. To bridge the gap between research and patient care, Renal Cell Cancer Update utilizes one-on-one interviews and roundtable discussions with leading oncology investigators. By providing access to the latest research developments and expert perspectives, this CME activity assists medical oncologists in the formulation of up-to-date clinical management strategies.

GLOBAL LEARNING OBJECTIVES

• Describe the biology underlying clear cell RCC, including inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene and the pathway leading to VEGF overexpression.
• Examine current treatment options for advanced renal cell carcinoma, including the safety and efficacy of targeted molecular and biologic therapies inhibiting VEGF, PDGF and EGF receptors.
• Evaluate the impact of pathologic grade and clinical risk on the selection of therapies and outcomes in RCC.
• Develop a therapeutic approach for the sequencing and duration of treatment with novel targeted therapies for the management of RCC.
• Describe ongoing studies in the adjuvant and metastatic settings in order to counsel appropriately selected patients regarding participation.

PURPOSE OF THIS ISSUE OF RENAL CEL CANCER UPDATE

The purpose of Issue 2 of Renal Cell Cancer Update is to support these global objectives by offering the perspectives of Drs Quinn, Stadler, Lacouture and Escudier on the integration of emerging clinical research data into the management of renal cell cancer.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 2.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains both audio and print components. To receive credit, the participant should listen to the CDs, review the Internet content and complete the Post-test and Evaluation Form located at www.RenalCellCancerUpdate.com/CME. www.RenalCellCancerUpdate.com contains edited comments, clinical trial schemas, graphics and references that supplement the audio program, as well as links to relevant full-text articles, abstracts, trial information and other web resources.

---

This program is supported by education grants from Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc and Genentech BioOncology.

Home

Editor
Neil Love, MD

Interviews

David I Quinn, MBBS, PhD
- Select publications

Walter Stadler, MD
- Select publications

Mario Lacouture, MD
- Select publications

Bernard J Escudier, MD
- Select publications

CME Information

Faculty Disclosures

Editor's Office